These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 8428872

  • 1. A double-blind placebo controlled study of desipramine in the treatment of ADD: III. Lack of impact of comorbidity and family history factors on clinical response.
    Biederman J, Baldessarini RJ, Wright V, Keenan K, Faraone S.
    J Am Acad Child Adolesc Psychiatry; 1993 Jan; 32(1):199-204. PubMed ID: 8428872
    [Abstract] [Full Text] [Related]

  • 2. A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy.
    Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS.
    J Am Acad Child Adolesc Psychiatry; 1989 Sep; 28(5):777-84. PubMed ID: 2676967
    [Abstract] [Full Text] [Related]

  • 3. Bupropion hydrochloride in attention deficit disorder with hyperactivity.
    Conners CK, Casat CD, Gualtieri CT, Weller E, Reader M, Reiss A, Weller RA, Khayrallah M, Ascher J.
    J Am Acad Child Adolesc Psychiatry; 1996 Oct; 35(10):1314-21. PubMed ID: 8885585
    [Abstract] [Full Text] [Related]

  • 4. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
    Klassen AF, Miller A, Fine S.
    Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
    [Abstract] [Full Text] [Related]

  • 5. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder.
    Wilens TE, Biederman J, Prince J, Spencer TJ, Faraone SV, Warburton R, Schleifer D, Harding M, Linehan C, Geller D.
    Am J Psychiatry; 1996 Sep; 153(9):1147-53. PubMed ID: 8780417
    [Abstract] [Full Text] [Related]

  • 6. Psychiatric comorbidity in attention deficit disorder: impact on the interpretation of Child Behavior Checklist results.
    Steingard R, Biederman J, Doyle A, Sprich-Buckminster S.
    J Am Acad Child Adolesc Psychiatry; 1992 May; 31(3):449-54. PubMed ID: 1592776
    [Abstract] [Full Text] [Related]

  • 7. Response to desipramine treatment in adolescent major depression.
    Boulos C, Kutcher S, Marton P, Simeon J, Ferguson B, Roberts N.
    Psychopharmacol Bull; 1991 May; 27(1):59-65. PubMed ID: 1862207
    [Abstract] [Full Text] [Related]

  • 8. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
    Research Units on Pediatric Psychopharmacology Autism Network.
    Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
    [Abstract] [Full Text] [Related]

  • 9. The treatment of attention-deficit hyperactivity disorder in Tourette's syndrome: a double-blind placebo-controlled study with clonidine and desipramine.
    Singer HS, Brown J, Quaskey S, Rosenberg LA, Mellits ED, Denckla MB.
    Pediatrics; 1995 Jan; 95(1):74-81. PubMed ID: 7770313
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 11. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder.
    Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, Mick E, Aleardi M, Herzig K, Faraone S.
    Biol Psychiatry; 2005 Mar 01; 57(5):456-63. PubMed ID: 15737659
    [Abstract] [Full Text] [Related]

  • 12. Desipramine treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette's syndrome.
    Spencer T, Biederman J, Kerman K, Steingard R, Wilens T.
    J Am Acad Child Adolesc Psychiatry; 1993 Mar 01; 32(2):354-60. PubMed ID: 8444765
    [Abstract] [Full Text] [Related]

  • 13. Desipramine treatment of cocaine-dependent patients with depression: a placebo-controlled trial.
    McDowell D, Nunes EV, Seracini AM, Rothenberg J, Vosburg SK, Ma GJ, Petkova E.
    Drug Alcohol Depend; 2005 Nov 01; 80(2):209-21. PubMed ID: 15913920
    [Abstract] [Full Text] [Related]

  • 14. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A, Scherer N, SPD503 Study Group.
    Pediatrics; 2008 Jan 01; 121(1):e73-84. PubMed ID: 18166547
    [Abstract] [Full Text] [Related]

  • 15. Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder.
    Lydiard RB, Morton WA, Emmanuel NP, Zealberg JJ, Laraia MT, Stuart GW, O'Neil PM, Ballenger JC.
    Psychopharmacol Bull; 1993 Jan 01; 29(2):183-8. PubMed ID: 8290663
    [Abstract] [Full Text] [Related]

  • 16. Alprazolam: an antidepressant? Alprazolam, desipramine, and an alprazolam-desipramine combination in the treatment of adult depressed outpatients.
    Fawcett J, Edwards JH, Kravitz HM, Jeffriess H.
    J Clin Psychopharmacol; 1987 Oct 01; 7(5):295-310. PubMed ID: 3316312
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ, Abikoff HB, Connor DF, Biederman J, Pliszka SR, Boellner S, Read SC, Pratt R.
    Clin Ther; 2006 Mar 01; 28(3):402-18. PubMed ID: 16750455
    [Abstract] [Full Text] [Related]

  • 18. A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder.
    Spencer T, Biederman J, Coffey B, Geller D, Crawford M, Bearman SK, Tarazi R, Faraone SV.
    Arch Gen Psychiatry; 2002 Jul 01; 59(7):649-56. PubMed ID: 12090818
    [Abstract] [Full Text] [Related]

  • 19. Psychiatric comorbidity among referred juveniles with major depression: fact or artifact?
    Biederman J, Faraone S, Mick E, Lelon E.
    J Am Acad Child Adolesc Psychiatry; 1995 May 01; 34(5):579-90. PubMed ID: 7775353
    [Abstract] [Full Text] [Related]

  • 20. Affective and anxiety comorbidity in post-traumatic stress disorder treatment trials of sertraline.
    Brady KT, Clary CM.
    Compr Psychiatry; 2003 May 01; 44(5):360-9. PubMed ID: 14505296
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.